Skip to main content

Advertisement

SpringerLink
Log in

The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside

  • Review Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

Since 2013, informative trials exploring the optimal use of available biologic agents in the first-line setting of metastatic colorectal cancer (mCRC) have been presented. These trials have opened a stimulating debate on the biological effect that first-line therapies may have on subsequent lines of treatment even long after the first-line progression.

Materials and methods

We reviewed available preclinical and clinical data on the effect of different sequences of the biological drugs approved for use in mCRC patients. The importance of molecular selection of patients based on RAS mutational status and toxicity and quality-of-life issues were also analyzed.

Results

Convincing evidence exists on the optimal therapeutic effect obtained by using anti-EGFR agents in first-line treatment before anti-VEGF agents. On the contrary, up-front anti-VEGF agents’ use seems to determine biological changes that increase the risk of acquired resistance to subsequent EGFR inhibitors. This hypothesis is confirmed by the scarce evidence of EGFR inhibitor activity in second-line treatment. Such a therapeutic optimum is subject to a fine molecular selection based on RAS mutational status.

Conclusion

There is accumulating evidence suggesting that, after precise and well-established molecular selection, anti-EGFR agents deliver their maximum efficacy in mCRC patients when given early in the treatment strategy. Their toxicity profile seems manageable under the supervision of experienced physicians. Large randomized trials prospectively confirming the impact of different sequencing strategies are eagerly awaited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Heinemann V, von Weikersthal LF, Decker T et al (2013) Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRASwildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Proc Am Soc Clin Oncol 31:LBA3506

    Google Scholar 

  2. Schwartzberg LS, Rivera F, Karthaus M et al (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:2240–2247

    Article  CAS  PubMed  Google Scholar 

  3. Venook AP, Niedzwiecki D, Lenz HJ et al (2014) CALGB/SWOG 80405: phase III trial of irinotecan/5- FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Proc Am Soc Clin Oncol 32(suppl):LBA3

    Google Scholar 

  4. Zeng M, Kikuchi H, Pino MS, Chung DC (2010) Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One 5(6):e10966

    Article  PubMed  PubMed Central  Google Scholar 

  5. Stefanini MO, Wu FT (2010) Mac Gabhann F, Popel AS. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 70(23):9886–9894

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kopetz S, Hoff PM, Morris JS et al (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28(3):453–459

    Article  CAS  PubMed  Google Scholar 

  7. Derangère V, Fumet JD, Boidot R et al (2016) Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget. doi:10.18632/oncotarget.7008. [Epub ahead of print]

  8. Mimeault M, Batra SK (2013) Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 17(1):30–54

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhou J, Wang J, Zeng Y et al (2015) Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer. Oncotarget. doi:10.18632/oncotarget.6293. [Epub ahead of print]

  10. Siravegna G, Mussolin B, Buscarino M et al (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21(7):795–801

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhang X, Gaspard JP, Chung DC (2001) Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 61(16):6050–6054

    CAS  PubMed  Google Scholar 

  12. Bianco R, Rosa R, Damiano V et al (2008) Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14(16):5069–5080

    Article  CAS  PubMed  Google Scholar 

  13. Ciardiello F, Bianco R, Caputo R et al (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10(2):784–793

    Article  CAS  PubMed  Google Scholar 

  14. Viloria-Petit A, Crombet T, Jothy S et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61(13):5090–6101

    CAS  PubMed  Google Scholar 

  15. Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15(10):1065–1075

    Article  CAS  PubMed  Google Scholar 

  16. Stintzing S, Modest DP, von Weikersthal LF et al (2014) Lba11:independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in fire-3 (aio krk-0306) in the final ras evaluable population. Ann Oncol. doi:10.1093/annonc/mdu438.9

    PubMed  PubMed Central  Google Scholar 

  17. Rivera F, Koukakis R, Karthaus M, Hecht et al (2015) PD-014. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC). Ann Oncol 26(suppl 4):101–107

    Article  Google Scholar 

  18. Heinemann V, Stintzing S, Modest DP et al (2015) Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 51(14):1927–1936

    Article  PubMed  Google Scholar 

  19. Modest DP, Stintzing S, von Weikersthal LF et al (2015) Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus Cetuximab or Bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol 33(32):3718–3726

    Article  CAS  PubMed  Google Scholar 

  20. Venook A, Niedzwiecki D, Lenz HJ et al (2015) CALGB/SWOG 80405: phase III trial of irinotecan/5-fu/leucovorin (FOLFIRI) or oxaliplatin/5-fu/leucovorin (mFOLFOX6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with kras wild-type (wt) untreated metastatic adenocarcinoma of the colon. Ann Oncol 25(suppl 2):ii112–ii113

    Article  Google Scholar 

  21. Khattak MA, Martin H, Davidson A, Phillips M (2015) Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials. Clin Colorectal Cancer 14(2):81–90

    Article  PubMed  Google Scholar 

  22. Pietrantonio F, Cremolini C, Petrelli F et al (2015) First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 96(1):156–166

    Article  PubMed  Google Scholar 

  23. Tamburini E, Rudnas B, Gianni L et al (2015) Anti-EGFR or Bevacizumab in first line treatment of RAS wild type metastatic colorectal neoplasm (RwtMCRC): meta-analysis of randomized clincal trials. Ann Oncol 26(suppl 6):vi36–vi52

    Article  Google Scholar 

  24. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26(14):2311–2319

    Article  CAS  PubMed  Google Scholar 

  25. Langer C, Kopit J, Awad M et al (2008) Analysis of k-ras mutations in patients with metastatic colorectal cancer receiving cetuximab in combination with irinotecan: results from the epic trial. Ann Oncol 19(Supplement):8. doi:10.1093/annonc/mdn507.viii.133

    Google Scholar 

  26. Seymour MT, Brown SR, Middleton G et al (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 14(8):749–759

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Peeters M, Price TJ, Cervantes A et al (2014) Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 25(1):107–116

    Article  CAS  PubMed  Google Scholar 

  28. Peeters M, Oliner KS, Price TJ et al (2015) Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin Cancer Res 21(24):5469–5479

    Article  CAS  PubMed  Google Scholar 

  29. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25(12):1539–1544

    Article  CAS  PubMed  Google Scholar 

  30. Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30(28):3499–3506

    Article  PubMed  Google Scholar 

  31. Tabernero J, Van Cutsem E, Lakomý R et al (2014) Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50(2):320–331

    Article  CAS  PubMed  Google Scholar 

  32. Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14(1):29–37

    Article  CAS  PubMed  Google Scholar 

  33. Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16(5):499–508

    Article  CAS  PubMed  Google Scholar 

  34. Cascinu S, Lonardi S, Rosati G et al (2015) A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab). Eur J Cancer 51(suppl 3):S329

    Article  Google Scholar 

  35. Hecht JR, Cohn A, Dakhil S et al (2015) SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer. Clin Colorectal Cancer. 14(2):72–80

    Article  PubMed  Google Scholar 

  36. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757–1765

    Article  CAS  PubMed  Google Scholar 

  37. Hess GP, Wang PF, Quach D et al (2010) Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract. 6(6):301–307

    Article  PubMed  PubMed Central  Google Scholar 

  38. Abrams TA, Meyer G, Schrag D et al (2014) Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst 106(2):djt371

    Article  PubMed  Google Scholar 

  39. Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fl uorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214

    Article  CAS  PubMed  Google Scholar 

  40. Loupakis F, Cremolini C, Masi G et al (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371(17):1609–1618

    Article  PubMed  Google Scholar 

  41. Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16(13):1306–1315

    Article  CAS  PubMed  Google Scholar 

  42. Cremolini C, Loupakis F, Antoniotti C et al (2015) Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann Oncol 26(6):1188–1194

    Article  CAS  PubMed  Google Scholar 

  43. Gruenberger T, Bridgewater J, Chau I et al (2015) Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 26(4):702–708

    Article  CAS  PubMed  Google Scholar 

  44. Ranpura V, Hapani S, Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305(5):487–494

    Article  CAS  PubMed  Google Scholar 

  45. Lacouture ME, Mitchell EP, Piperdi B et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351–1357

    Article  CAS  PubMed  Google Scholar 

  46. Kobayashi Y, Komatsu Y, Yuki S et al (2015) Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: hGCSG1001 study. J-STEPP. Future Oncol. 11(4):617–627

    Article  CAS  PubMed  Google Scholar 

  47. Melosky B, Anderson H, Burkes RL et al (2015) Pan canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer. J Clin Oncol. pii: JCO.2015.62.3918. [Epub ahead of print]

  48. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408–1417

    Article  PubMed  Google Scholar 

  49. Láng I, Köhne CH, Folprecht G et al (2013) Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. Eur J Cancer 49(2):439–448

    Article  PubMed  Google Scholar 

  50. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ (2015) Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112(12):1888–1894

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yoshino T, Uetake H, Tsuchihara K et al. (2016) PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. J Clin Oncol 34, (suppl 4S; abstr TPS776)

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Dept, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy

    A. Zaniboni

  2. Medical Oncology Unit, Tor Vergata University Hospital, Rome, Italy

    V. Formica

Authors
  1. A. Zaniboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Formica
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Zaniboni.

Ethics declarations

Conflict of interest

The authors have declared no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaniboni, A., Formica, V. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. Cancer Chemother Pharmacol 78, 233–244 (2016). https://doi.org/10.1007/s00280-016-3032-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-016-3032-8

Keywords

Search

Navigation